ArticleClinical and molecular hepatology2022
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area.
Article in Clinical and molecular hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Mannose receptor-targeted MSC-derived exosomes as a high-affinity delivery platform for liver sinusoidal endothelial cells.Drug delivery and translational research · 2026Article
- Sex Disparity in Cancer and Non-cancer Mortality among Korean Cancer Survivors.Journal of cancer prevention · 2025Article
- Pharmacological Evaluation ofCurrent issues in molecular biology · 2025Article
- Bioactive Secondary Metabolites fromCurrent pharmaceutical design · 2025Article
- Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.Cancer management and research · 2025Article
- Development and validation of a nomogram for predicting moderate-to-severe pain in hepatitis B virus-related liver cancer patients after CyberKnife treatment.American journal of translational research · 2025Article
- Article
- Association between Unplanned Conversion and Patient Survival after Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Propensity Score Matched Analysis.Journal of clinical medicine · 2024Article
- Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma.BMC cancer · 2023Article
- Article
- Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019.Annals of hepato-biliary-pancreatic surgery · 2022Article
- Risk factors for postoperative portal vein thrombosis in patients with hepatitis B liver cancer and its impact on mortality-a retrospective study.Translational cancer research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsPrimary liver cancer is one of the leading causes of cancer mortality worldwide. However, the causes of death have not been studied in detail in patients with liver cancer.
methodsThe causes of death and cause-specific mortality risks in patients with primary liver cancer, diagnosed during 2000-2016, were investigated using the nationwide population-based cancer registry data in South Korea (n=231,388). The cumulative incidence function and Fine-Gray models were used to estimate the cause-specific mortality under the competing risks. Risks of non-cancer deaths relative to the general population were compared by standardized mortality ratios (SMRs).
resultsAmong 179,921 total deaths, 92.4%, 1.7%, and 6.0% of patients died of primary liver cancer, cancer from other sites, and non-cancer illnesses, respectively. Proportionate mortality from liver cancer remained high. The 5-year competing risks probability of death from liver cancer varied by tumor stage, from 42% to 94%, and it remained high 10 years after the diagnosis (61-95%). Competing mortality from other causes has continuously increased. The most common non-cancer causes of death were underlying liver diseases (SMR, 15.6; 95% confidence interval [CI], 15.1-16.1) and viral hepatitis (SMR, 46.5; 95% CI, 43.9-49.2), which demonstrated higher mortality risks compared to the Korean general population. Higher mortality risks of suicide (SMR, 2.6; 95% CI, 2.4-2.8) was also noted.
conclusionPatients with liver cancer are most likely to die from liver cancer and related liver disease, even 10 years after the diagnosis, highlighting a need for specialized long-term follow-up care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.